CA3129890A1 - Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells - Google Patents

Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells Download PDF

Info

Publication number
CA3129890A1
CA3129890A1 CA3129890A CA3129890A CA3129890A1 CA 3129890 A1 CA3129890 A1 CA 3129890A1 CA 3129890 A CA3129890 A CA 3129890A CA 3129890 A CA3129890 A CA 3129890A CA 3129890 A1 CA3129890 A1 CA 3129890A1
Authority
CA
Canada
Prior art keywords
seq
antibody
light chain
set forth
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129890A
Other languages
English (en)
French (fr)
Inventor
Raymond COMENZO
Wagner Zago
Nina Mercedes ASHTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Tufts Medical Center Inc
Original Assignee
Prothena Biosciences Ltd
Tufts Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Tufts Medical Center Inc filed Critical Prothena Biosciences Ltd
Publication of CA3129890A1 publication Critical patent/CA3129890A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3129890A 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells Pending CA3129890A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804721P 2019-02-12 2019-02-12
US62/804,721 2019-02-12
PCT/US2019/066648 WO2020167376A1 (en) 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Publications (1)

Publication Number Publication Date
CA3129890A1 true CA3129890A1 (en) 2020-08-20

Family

ID=69182616

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129890A Pending CA3129890A1 (en) 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Country Status (17)

Country Link
US (2) US20220213223A1 (https=)
EP (1) EP3923954A1 (https=)
JP (2) JP2022520572A (https=)
KR (1) KR20210143752A (https=)
CN (2) CN113924099A (https=)
AU (2) AU2019429147B2 (https=)
BR (1) BR112021015870A2 (https=)
CA (1) CA3129890A1 (https=)
CL (1) CL2021002140A1 (https=)
EA (1) EA202192235A1 (https=)
IL (1) IL285480A (https=)
JO (1) JOP20210220A1 (https=)
MA (1) MA54923A (https=)
MX (1) MX2021009687A (https=)
PH (1) PH12021551960A1 (https=)
SG (1) SG11202108767PA (https=)
WO (1) WO2020167376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4582446A3 (en) 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
ES2914781T3 (es) * 2016-06-30 2022-06-16 Prothena Biosciences Ltd Composiciones para el tratamiento de la amiloidosis

Also Published As

Publication number Publication date
US20250075007A1 (en) 2025-03-06
WO2020167376A1 (en) 2020-08-20
KR20210143752A (ko) 2021-11-29
EA202192235A1 (ru) 2022-01-19
CL2021002140A1 (es) 2022-04-18
US20220213223A1 (en) 2022-07-07
PH12021551960A1 (en) 2022-07-18
AU2019429147A1 (en) 2021-09-09
CN113924099A (zh) 2022-01-11
WO2020167376A8 (en) 2020-10-29
MA54923A (fr) 2021-12-22
JOP20210220A1 (ar) 2023-01-30
AU2019429147B2 (en) 2024-11-14
BR112021015870A2 (pt) 2021-11-03
IL285480A (en) 2021-09-30
SG11202108767PA (en) 2021-09-29
CN119950702A (zh) 2025-05-09
JP2025015588A (ja) 2025-01-30
JP2022520572A (ja) 2022-03-31
EP3923954A1 (en) 2021-12-22
AU2025200997A1 (en) 2025-03-13
MX2021009687A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
MX2007000748A (es) Metodos para tratar el sindrome de sjogren.
JP7160533B2 (ja) 多発性骨髄腫（ｍｍ）の処置
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
US20210079078A1 (en) Compositions for Treating Amyloidosis
JP2024534602A5 (https=)
KR20220019656A (ko) 경쇄 아밀로이드증 치료 방법
TW202346342A (zh) 抗tim-3抗體與抗pd-1抗體的藥物組合
JP2020521777A (ja) 抗ｃｄ１９抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム
US20240343822A1 (en) Treatment of anti-pla2r autoantibody-mediated membranous nephropathy
JP2022520572A5 (https=)
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
EA047876B1 (ru) Лечение al-амилоидоза комбинацией моноклональных антител против легких цепей иммуноглобулина и молекул клеточной мембраны cd38 в продуцирующих антитела и других иммунных клетках
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
CN117815387A (zh) Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
HK40100364A (zh) 减少人类受试者中的tau的方法
CN119031933A (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
CA3095100A1 (en) Treatment and prophylaxis of amyloidosis
HK40008815B (en) Compositions for treating amyloidosis

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250603

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128